Million-Yuan CAR-T Cancer Therapy Included in Basic Medical Insurance for the First Time, Patients' Out-of-Pocket Costs Cut to Under 100,000 Yuan
2 day ago / Read about 0 minute
Author:小编   

The 2026 Conference on High-Quality Development of Innovative Drugs announced the latest version of the National Basic Medical Insurance Drug Catalog and the Commercial Insurance Innovative Drug Catalog. In the new basic medical insurance catalog, two innovative drugs have been transferred from the first edition of the commercial insurance innovative drug catalog into basic medical insurance, reflecting a further deepening of the coordinated linkage between the "basic medical insurance + commercial insurance" dual catalogs. Among them, the million-yuan CAR-T cancer therapy has achieved a historic breakthrough: JW Therapeutics' relma-cel injection (brand name: Carteyva®) has been included in basic medical insurance for the first time, reducing patients' out-of-pocket costs after reimbursement to under 100,000 yuan. The core reason this "sky-high-priced drug" was able to enter basic medical insurance with a substantial price reduction lies in the localization of key raw materials, which has greatly compressed production costs.